B
Benoit Peyronnet
Researcher at University of Rennes
Publications - 303
Citations - 4068
Benoit Peyronnet is an academic researcher from University of Rennes. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 195 publications receiving 2522 citations.
Papers
More filters
Journal ArticleDOI
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Marko Babjuk,Marko Babjuk,Maximilian Burger,Eva Comperat,Paolo Gontero,A. Hugh Mostafid,Joan Palou,Bas W.G. van Rhijn,Bas W.G. van Rhijn,Morgan Rouprêt,Shahrokh F. Shariat,Richard Sylvester,Richard Zigeuner,Otakar Čapoun,Daniel Cohen,José Luis Dominguez Escrig,Virginia Hernández,Benoit Peyronnet,Thomas Seisen,Viktor Soukup +19 more
TL;DR: The European Association of Urology Non-muscle-invasive Bladder Cancer (NMIBC) Panel has released an updated version of their guidelines, which contains information on classification, risk factors, diagnosis, prognostic factors, and treatment of NMIBC.
Journal ArticleDOI
Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel
Thomas Seisen,Benoit Peyronnet,J. Domínguez-Escrig,Harman Maxim Bruins,Cathy Yuhong Yuan,Marko Babjuk,Andreas Böhle,Maximilian Burger,Eva Comperat,Nigel C. Cowan,Eero Kaasinen,Joan Palou,Bas W.G. van Rhijn,Richard Sylvester,Richard Zigeuner,Shahrokh F. Shariat,Morgan Rouprêt +16 more
TL;DR: A systematic review of studies that compared kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma found similar oncologic outcomes for favourable tumours when using ureteroscopic or percutaneous management, whereas indications for segmental ureteretectomy could be extended to selected cases of aggressive tumours.
Journal ArticleDOI
A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.
Benoit Peyronnet,Emma Mironska,Christopher R. Chapple,Linda Cardozo,Matthias Oelke,Roger R. Dmochowski,Gérard Amarenco,Xavier Gamé,Roger Kirby,Frank Van der Aa,Jean-Nicolas Cornu +10 more
TL;DR: OAB is seen as a complex, multifactorial symptom syndrome, resulting from multiple potential pathophysiological mechanisms, and there is a temptation to label OAB as "idiopathic" without obvious causation.
Journal ArticleDOI
Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors
Benoit Peyronnet,Thomas Seisen,Emmanuel Oger,Christophe Vaessen,Y. Grassano,Thibaut Benoit,Julie Carrouget,Benjamin Pradere,Zineddine Khene,Anthony Giwerc,Romain Mathieu,Jean-Baptiste Beauval,François-Xavier Nouhaud,Pierre Bigot,Nicolas Doumerc,Jean-Christophe Bernhard,Arnaud Mejean,Jean-Jacques Patard,Sharokh Shariat,Morgan Rouprêt,Karim Bensalah +20 more
TL;DR: RPN was less morbid than OPN, with lower complications, less blood loss, and a shorter hospital of stay, and the intermediate-term oncologic outcomes were similar in the two groups.
Journal ArticleDOI
Immunotherapy in Renal Cell Carcinoma: The Future Is Now
Antoine Deleuze,Judikaël Saout,Frédéric Dugay,Benoit Peyronnet,Romain Mathieu,Gregory Verhoest,Karim Bensalah,Laurence Crouzet,Brigitte Laguerre,Marc-Antoine Belaud-Rotureau,N. Rioux-Leclercq,Solène-Florence Kammerer-Jacquet +11 more
TL;DR: There is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients to meet the unmet need of Renal cell carcinoma.